Tactile Systems Technology, Inc. Share Price

Equities

TCMD

US87357P1003

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 21:00:00 11/07/2024 BST 5-day change 1st Jan Change
11.8 USD +2.61% Intraday chart for Tactile Systems Technology, Inc. +3.24% -17.48%
Sales 2024 * 303M 23.37B Sales 2025 * 341M 26.32B Capitalization 280M 21.63B
Net income 2024 * 13M 1B Net income 2025 * 22M 1.7B EV / Sales 2024 * 0.93 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 0.82 x
P/E ratio 2024 *
21.3 x
P/E ratio 2025 *
13.4 x
Employees 992
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.49%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.61%
1 week+3.24%
Current month-1.17%
1 month-2.72%
3 months-21.59%
6 months-17.54%
Current year-17.48%
More quotes
1 week
11.19
Extreme 11.19
12.01
1 month
11.12
Extreme 11.12
12.18
Current year
11.12
Extreme 11.12
16.95
1 year
9.70
Extreme 9.695
26.11
3 years
6.28
Extreme 6.28
50.85
5 years
6.28
Extreme 6.28
71.65
10 years
6.28
Extreme 6.28
76.63
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 31/12/20
Director of Finance/CFO 49 19/03/23
Chief Operating Officer - 31/10/21
Members of the board TitleAgeSince
Chairman 64 31/08/15
Director/Board Member 65 19/09/17
Director/Board Member 59 01/10/23
More insiders
Date Price Change Volume
11/07/24 11.8 +2.61% 431,202
10/07/24 11.5 -0.52% 577,204
09/07/24 11.56 +0.17% 414,324
08/07/24 11.54 +2.21% 409,853
05/07/24 11.29 -1.22% 435,631

Delayed Quote Nasdaq, July 11, 2024 at 09:00 pm

More quotes
Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company providing therapies for people with chronic disorders. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. The Company markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. The Company's Entre system is a basic pneumatic compression device. Kylee, its free mobile application, helps patients learn about lymphedema.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
11.8 USD
Average target price
20.67 USD
Spread / Average Target
+75.14%
Consensus